This inventor holds 6 USPTO granted patents and 1 EPO patent. Top assignees: Sumitomo Dainippon Pharma Co., Ltd., Sumitomo Pharma Co., Ltd.. Active years: 2017-2025.
Company Filing History:
3 out of 110 
3 out of 66 Years Active: 2017-2025
Title: Miki Hashizume: Innovator in Anti-Tumor Agents
Introduction
Miki Hashizume is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-tumor agents. With a total of 6 patents, her work focuses on innovative compounds that target cancer cells.
Latest Patents
One of her latest patents involves dihydrochromene derivatives. This invention relates to a compound that serves as a novel anti-tumor agent targeting cancer stem cells (CSCs). These CSCs are believed to play a crucial role in the persistent proliferation of malignant tumors, metastasis, recurrence of cancer, and resistance to anti-tumor agents. Another significant patent is for a 1,4-disubstituted imidazole derivative. This compound exhibits a potent inhibitory effect on the sphere-forming capacity of cancer cells and is useful as an orally-available anti-tumor agent.
Career Highlights
Miki Hashizume has worked with notable companies such as Sumitomo Dainippon Pharma Co., Ltd. and Sumitomo Pharma Co., Ltd. Her experience in these organizations has contributed to her expertise in pharmaceutical innovations.
Collaborations
Throughout her career, Miki has collaborated with esteemed colleagues, including Hitoshi Ban and Manabu Kusagi. These partnerships have further enhanced her research and development efforts in the field of anti-cancer therapies.
Conclusion
Miki Hashizume's innovative work in developing anti-tumor agents showcases her dedication to advancing cancer treatment. Her contributions are vital in the ongoing fight against cancer, and her patents reflect her commitment to improving patient outcomes.